Vertex Pharmaceuticals News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

09.07.13	Vertex Kalydeco Gets Australian Regulatory Approval (RTTNews)
30.08.12	Moody's affirms 17 CMBS classes of MSC 2003-IQ6 (Moodys)
14.05.12	Vertex Pharmaceuticals: Setzt Höhenflug nach verbessertem Analystenrating fort (Aktiencheck)
16.12.11	Wall Street Schluss: Wenig verändert ins Wochenende, Zynga-Aktie fällt unter den Ausgabepreis (Aktiencheck)
16.12.11	Vertex Pharmaceuticals präsentiert neuen CEO (Aktiencheck)
25.02.10	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences (Businesswire)
16.02.10	Vertex Pharmaceuticals Announces Redemption Date for 4.75% Convertible Senior Subordinated Notes due 2013 (Businesswire)
04.02.10	Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs (Businesswire)
11.01.10	Vertex Reviews 2010 Business Priorities to Support Goal of Becoming Fully-Capable Biopharmaceutical Company (Businesswire)
26.10.09	Vertex Pharmaceuticals Reports Third Quarter 2009 Financial Results and Highlights Recent Business and Clinical Progress (Businesswire)
18.09.09	Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences (Businesswire)
04.05.09	Vertex Promotes Dr. Peter Mueller to Global R&D Chief and Chief Science Officer (Businesswire)
25.04.09	Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study (Businesswire)
16.04.09	Vertex Pharmaceuticals Reviews First Quarter Business Progress and Reports First Quarter 2009 Financial Results (Businesswire)
03.03.09	Vertex Pharmaceuticals Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir (Businesswire)
05.02.09	Vertex Pharmaceuticals Announces Transition in Company Leadership (Businesswire)
01.11.08	New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection (Businesswire)
13.03.08	Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients (Businesswire)
20.11.07	Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	296.10	1.13 %	K V
Logitech Intl	73.30	0.38 %	K V
Lonza Grp	530.00	0.34 %	K V
ABB	48.86	0.27 %	K V
Givaudan	3’917.00	0.26 %	K V
Nestle	73.58	-0.84 %	K V
Geberit	512.00	-0.89 %	K V
Holcim	86.16	-0.94 %	K V
Zurich Insur Gr	532.40	-1.08 %	K V
Sika	213.00	-2.56 %	K V

mehr

15:58		Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer
15:58		Börse Frankfurt: So steht der LUS-DAX am Nachmittag
15:58		Börse Frankfurt: DAX präsentiert sich nachmittags leichter
15:58		Anleger in London halten sich zurück: So bewegt sich der FTSE 100 aktuell
15:58		Handel in Zürich: SMI verbucht Verluste
13:22		GSK-Aktie verliert: GSK erreicht Fortschritte bei Eierstockkrebs-Therapie
12:26		LSE-Handel FTSE 100 am Freitagmittag in Rot
12:26		Anleger in Zürich halten sich zurück: SMI am Freitagmittag in Rot